ARTICLE | Company News

Myriad Genetics pharmacogenetics news

November 3, 2014 8:00 AM UTC

Myriad established a European lab for its companion diagnostic Tumor BRACAnalysis CDx. The test identifies patients with breast cancer 1 early onset (BRCA1) and BRCA2 mutations who may benefit from treatment with poly(ADP-ribose) polymerase (PARP) inhibitors, such as Lynparza olaparib from AstraZeneca plc (LSE:AZN; NYSE:AZN, London, U.K.). ...